CMS Wants To Help With Medicaid Outcomes-Based Reimbursement For Cell And Gene Therapy

Center for Medicare and Medicaid Innovation (CMMI) deputy director Ellen Lukens talked about the goals and challenges of a new voluntary program the agency will test with state Medicaid programs.

Medicaid
• Source: Shutterstock

The US Centers for Medicare and Medicaid Services (CMS) is optimistic that a new voluntary program it expects to launch in 2025 that could help pave the way for broader access to expensive cell and gene therapies under Medicaid, while also saving the government money.

Center for Medicare and Medicaid Innovation (CMMI) deputy director Ellen Lukens discussed some of the goals of the program – and some of the barriers that need to be overcome – during a

More from Gene Therapies

Which Firms Are Most Exposed To Prasad’s Possible Accelerated Approvals Clampdown?

 

Vaccine and accelerated approvals are expected to face greater scrutiny under new CBER leader Vinay Prasad, but he has promised “no light switch change” to policy, giving some reassurance to companies whose share prices have been battered.

Abeona Sets $3.1m Price For Rare Skin Disorder Gene Therapy

 
• By 

Abeona plans to offer an outcomes-based payment model for Zevaskyn, which likely will see complementary use with Krystal’s Vyjuvek in recessive dystrophic epidermolysis bullosa patients.

Verve Moves Toward Lilly Opt-In For PCSK9 Program With Phase Ib Results

 

The company posted positive initial results from the Heart-2 trial in HeFH and CAD, with strong LDL cholesterol lowering and a clean safety profile.

Ferring’s Faith In Bladder Cancer Gene Therapy Starts To Pay Off

 
• By 

Adstiladrin sales hit €70m in first full year on the market

More from Advanced Therapies

Gilead Pipeline Progress Offsets Oncology Sales Slowdown

 

Sales of the company’s approved cancer therapies were weaker or down, but Trodelvy is likely to see a label expansion and cell therapies are making progress.

In Brief: BriaCell’s Breast Cancer Cell Therapy Boosts Survival In Phase II

 

BriaCell announced its cell therapy Bria-IMT plus checkpoint inhibitors bested Gilead’s Trodelvy in a Phase II trial in HR+ breast cancer; a Phase III trial is enrolling.

Verve Moves Toward Lilly Opt-In For PCSK9 Program With Phase Ib Results

 

The company posted positive initial results from the Heart-2 trial in HeFH and CAD, with strong LDL cholesterol lowering and a clean safety profile.